AstraZeneca's drug Fasenra flops in COPD trial

LONDON (Reuters) - AstraZeneca's said its first respiratory biologic medicine Fasenra failed to meet its target in a clinical trial treating patients with moderate to very severe chronic obstructive pulmonary disease (COPD).

from Reuters: Health News https://ift.tt/2jNXoFR